# Germany RNA-based Therapeutics Market > Germany RNA-Based Therapeutics Market Research Report: Size, Share, Trend Analysis By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Applications (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations) andBy Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.1% - **2024:** $ 732.65 Million - **2025:** $ 777.34 Million - **2035:** $ 1,405.55 Million - **Key Players:** Moderna (US), BioNTech (DE), Alnylam Pharmaceuticals (US), Ionis Pharmaceuticals (US), CureVac (DE), Sangamo Therapeutics (US), Arcturus Therapeutics (US), Translate Bio (US) **Report ID:** MRFR/Pharma/50892-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/germany-rna-based-therapeutics-market-52651 --- ## Market Summary ## **Germany RNA-Based Therapeutics Market Overview** As per MRFR analysis, the Germany RNA-Based Therapeutics Market Size was estimated at 385 (USD Million) in 2023. The Germany RNA-Based Therapeutics Market Industry is expected to grow from 424.5 (USD Million) in 2024 to 1,062.5 (USD Million) by 2035. The Germany RNA-Based Therapeutics Market CAGR (growth rate) is expected to be around 8.698% during the forecast period (2025 - 2035). ## **Key Germany RNA-Based Therapeutics Market Trends Highlighted** In Germany, the RNA-Based Therapeutics Market is experiencing significant growth driven by an increasing focus on personalized medicine and advancements in RNA technology. The German healthcare system supports innovation, fostering collaborations between biotechnology firms and research institutions, which enhances the development of RNA-based therapies. The regulatory environment in Germany is becoming more favorable, with agencies facilitating quicker approvals for innovative therapies, thereby speeding up the introduction of new RNA treatments to the market. Recent trends indicate a rising interest in mRNA vaccine technology, particularly following its success during the COVID-19 pandemic, which has paved the way for further exploration into RNA-based therapeutics for other diseases, such as cancer and genetic disorders. Furthermore, Germany's robust pharmaceutical sector, marked by well-known companies and new businesses, is aggressively funding RNA research and development, hence fostering a dynamic environment that fosters creativity. Improved public-private partnerships meant to hasten the implementation of RNA therapeutics will help to seize opportunities in the German market. Government projects' more financing helps to support research as well; programs supporting RNA technology investment help to drive this. There is an increasing need for focused treatments that can meet certain patient requirements, which fits the potential of RNA-based medicines. As the awareness of RNA therapies rises among clinicians and patients, the industry is poised for further expansion, underscoring the potential for significant advancements and commercial success in the German RNA-Based Therapeutics Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Germany RNA-Based Therapeutics Market Drivers** ### **Increasing Prevalence of Genetic Disorders** The incidence of genetic disorders is on the rise in Germany, leading to increased demand for RNA-based therapeutics. According to the German Federal Ministry of Health, it is estimated that approximately 10% of the population is affected by some form of genetic disorder. This rise is pushing the Germany RNA-Based Therapeutics Market Industry to innovate and develop novel treatments. Established organizations like BioNTech and CureVac are actively involved in Research and Development initiatives to address genetic disorders through RNA technologies. With nearly one in ten Germans potentially needing treatment, the market is projected to expand significantly due to this growing patient base. ### **Advancements in RNA Technology** Recent technological advancements in RNA therapeutics are enhancing the effectiveness and safety profiles of RNA-based treatments in Germany. The German Institute of Medical Technology has reported a 30% growth in funding for RNA technology projects between 2020 and 2023. Companies such as BioNTech have pioneered messenger RNA (mRNA) vaccines, showcasing the potential of RNA-based solutions in combating diseases like COVID-19. These advancements foster greater interest from investors and stakeholders, bolstering the growth of the Germany RNA-Based Therapeutics Market Industry. ### **Government Support for Bio-pharmaceutical Innovation** The German government has shown significant support for Bio-pharmaceutical innovation, facilitating market growth for RNA-based therapeutics. Initiatives like the 'Nationale Dekade gegen Krebs' aim to enhance cancer research and treatment, with a focus on RNA technologies. Reports indicate that funding for biomedical Research and Development has increased by 25% over the last five years. Initiatives by the Federal Ministry of Education and Research are also promoting collaborative efforts between academia and industries, ensuring a strong pipeline of RNA therapeutics in the Germany RNA-Based Therapeutics Market Industry. ### **Rising Demand for Personalized Medicine** The trend towards personalized medicine is driving the demand for RNA-based therapeutics in Germany. As highlighted by the German Society for Personalized Medicine, there has been a surge in the number of patients seeking tailored treatments that specifically address their genetic profiles. The market is projected to reach 1.5 million patients by 2030 who will benefit from such customized therapies. Companies like Morphosys are investing heavily in precision medicine targeting specific genetic markers, which is expected to further promote growth within the Germany RNA-Based Therapeutics Market Industry. ## **Germany RNA-Based Therapeutics Market Segment Insights** ### **RNA-Based Therapeutics Market Technology Insights** The Germany RNA-Based Therapeutics Market, particularly within the Technology segment, showcases significant advancements and a robust competitive landscape, supported by continuous Research and Development activities across various platforms. RNA Interference (RNAi) remains a critical element, enabling precise silencing of genes linked to various diseases, thus providing therapeutic options for conditions like genetic disorders and cancers. This technology has gained traction due to its ability to target specific RNA molecules, which helps to mitigate unwanted side effects, thereby drawing attention from both established players and startups in the biotechnology field. Antisense Oligonucleotides also represent an important area within this segment. These molecules are designed to bind to specific RNA transcripts and modify their expression, making them particularly valuable in treating hereditary diseases and other genetic conditions. The effectiveness and versatility of Antisense Oligonucleotides in addressing a range of diseases significantly bolsters the appeal of the technology in clinical settings, enhancing their presence in the Germany RNA-Based Therapeutics Market. Moreover, mRNA Therapeutics have gained widespread attention in recent years, primarily due to their acclaimed success in developing vaccines. The rapid advancements in mRNA technology not only hold promise for infectious diseases but also for cancer immunotherapy and other therapeutic applications, transforming how diseases are treated and creating opportunities for new therapeutic paradigms. In addition, CRISPR Technology is becoming increasingly significant due to its potential in gene editing. Its widespread applications extend to developing durable therapies for inherited diseases, further establishing its importance in the biotechnology landscape. CRISPR allows for accurate modifications at the genomic scale, paving the way for innovative treatment options that were previously thought unattainable. Collectively, these technologies underscore the dynamic nature of the Germany RNA-Based Therapeutics Market, where innovation, regulatory frameworks, and collaboration between academic institutions and industry stakeholders are driving an upward trajectory for advancements in RNA therapeutics. With the German government actively supporting biotechnology through funding initiatives and infrastructure development, the potential for market growth within this segment is tremendous, positioning Germany as a leader in RNA-Based Therapeutics innovations. The ongoing integration of cutting-edge technologies is likely to yield transformative applications across therapeutic areas, enhancing patient outcomes and expanding treatment possibilities in the foreseeable future. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **RNA-Based Therapeutics Market Application Insights** The Germany RNA-Based Therapeutics Market, particularly within the Application segment, is witnessing a notable evolution, driven by advances in genetic research and therapeutic innovations. Oncology stands out as a crucial area of focus, with RNA-based therapies aiming to target cancer cells effectively, offering tailored treatments that enhance patient outcomes. Infectious Diseases also represent a significant application, especially in light of recent global challenges, where RNA therapeutics can accelerate vaccine development and treatment efficacy. Genetic Disorders benefit from this market due to the potential of RNA therapeutics to correct or replace defective genes, exemplifying a shift towards personalized medicine. Cardiovascular Diseases showcase the versatility of RNA technologies, aimed at preventing and treating conditions by altering gene expression. With a growing emphasis on these applications in Germany, driven by government support and increasing investments in Research and Development, the market is positioned for robust growth. The combination of strong healthcare infrastructure and collaborative efforts among industry players is expected to foster innovation and improve patient care across these critical therapeutic areas, leading to substantial advancements in the Germany RNA-Based Therapeutics Market revenue and statistics in the coming years. ### **RNA-Based Therapeutics Market End Use Insights** The Germany RNA-Based Therapeutics Market exhibits significant activity in its End Use segment, encompassing key players such as Pharmaceutical Companies, Research Institutions, and Contract Research Organizations. Pharmaceutical Companies are critical in driving market growth due to their robust capabilities in drug development and commercialization, focusing on innovative RNA-based solutions to address various diseases. Research Institutions play a vital role as they contribute to foundational studies and translational research, making invaluable advancements in RNA technologies that ultimately benefit therapeutic applications. Furthermore, Contract Research Organizations are essential for providing specialized services and expertise, aiding Pharmaceutical Companies and Research Institutions in the early stages of drug development and facilitating clinical trials. This dynamic collaboration between these entities fosters a thriving ecosystem, enhancing Germany's position as a leader in the RNA therapeutics landscape. The increasing investment in RNA technologies, coupled with the rising prevalence of genetic and chronic diseases, presents substantial opportunities for all participants in this market. As a result, the Germany RNA-Based Therapeutics Market is positioned for continued innovation and growth, with each segment contributing to the overall health and sustainability of the industry. ### **RNA-Based Therapeutics Market Delivery Method Insights** The Delivery Method segment of the Germany RNA-Based Therapeutics Market holds significant importance as it addresses the challenges of effectively delivering therapeutic agents to target cells. Each approach within this segment, including Liposomes, Nanoparticles, Viral Vectors, and Electroporation, plays a critical role in enhancing the efficacy and safety of RNA-based treatments. Liposomes are known for their biocompatibility and ability to encapsulate RNA, ensuring stability and targeted delivery. Nanoparticles provide versatility in their design, allowing for tailored release profiles and improved cellular uptake, thus enhancing therapeutic effects. Viral Vectors exploit the natural ability of viruses to enter cells, making them highly effective for gene delivery. Electroporation, on the other hand, is gaining traction due to its ability to increase cell membrane permeability, facilitating the introduction of RNA into various cell types effectively. The continued evolution of these delivery methods in Germany is propelled by advancements in technology and an increasing focus on personalized medicine, contributing to the overall dynamics of the Germany RNA-Based Therapeutics Market. The robust research and development efforts in these delivery methods signal a promising future for RNA-based therapeutics, fostering opportunities for innovation and market growth. ## **Germany RNA-Based Therapeutics Market Key Players and Competitive Insights** The Germany RNA-Based Therapeutics Market is a dynamic and rapidly evolving sector characterized by increasing investments in research and development, a surge in the prevalence of genetic disorders, and advancements in delivery mechanisms for RNA molecules. This market is witnessing heightened competition as various biotechnology firms and pharmaceutical companies are developing innovative RNA-based therapies, including mRNA vaccines and RNA interference (RNAi) drugs. The competitive landscape is shaped by collaborations, partnerships, and strategic mergers, which aim to leverage advancements in genomics and biotechnology. Key market players are focusing on expanding their product pipelines and enhancing their clinical trial capabilities to address unmet medical needs, thereby driving growth and innovation in this field. Focusing on Arcturus Therapeutics within the Germany RNA-Based Therapeutics Market, the company has established a notable presence due to its commitment to developing transformative therapeutic solutions utilizing its proprietary LUNAR RNA delivery platform. The strengths of Arcturus lie in its innovative approach to RNA delivery, which seeks to improve bioavailability and therapeutic efficacy. In Germany, the company is well-positioned to leverage its technology to create treatments across various diseases, which contributes to its competitive edge. Arcturus’ collaboration with research institutions and strategic partnerships in Germany are expected to further cement its market position as they seek to align their therapeutic developments with local healthcare dynamics and regulatory standards. BioNTech plays a significant role in Germany's RNA-Based Therapeutics Market, particularly known for its groundbreaking work in mRNA technology. The company has achieved widespread acclaim for its key products, most notably its mRNA-based COVID-19 vaccine, which has set a benchmark for RNA therapeutics globally. In addition to its successful vaccine portfolio, BioNTech is actively pursuing the development of personalized cancer therapies and other infectious disease treatments that utilize its innovative mRNA platform. The company’s strengths include a robust pipeline of product candidates and a strong focus on research and innovation, supported by collaborations with leading academic institutions and industry partners. BioNTech is also known for its strategic mergers and acquisitions that enhance its technological capabilities and broaden its therapeutic targets within the German market, solidifying its reputation as a frontrunner in the RNA-based therapeutic landscape. ### **Key Companies in the Germany RNA-Based Therapeutics Market Include** ## **Germany RNA-Based Therapeutics Market Industry Developments** The Germany RNA-Based Therapeutics Market has seen significant developments in recent months. In September 2023, BioNTech announced a collaboration with GSK to further develop mRNA-based therapeutics for cancer treatment, highlighting the increasing focus on personalized medicine. Moreover, Moderna reported an extension of its manufacturing capabilities in Germany to facilitate the production of its mRNA vaccines and therapeutics, contributing to local employment and technological advancement. In July 2023, Pfizer and BioNTech’s joint venture reported promising results in their ongoing clinical trials for new mRNA therapies targeting infectious diseases. The market has also experienced growth, attributed to advancements in Research and Development by companies such as CureVac, which recently began a Phase 1 trial for its RNA-based cancer vaccine. There have been no recent mergers or acquisitions reported among the major companies, including Arcturus Therapeutics, Sangamo Therapeutics, and Evotec. The German government continues to support the biotechnology sector through funding and policies aimed at fostering innovation, further strengthening the market landscape for RNA-based therapeutics. These dynamics underscore the vital role that Germany plays in the advancement of RNA technology within the global healthcare framework. ## **Germany RNA-Based Therapeutics Market Segmentation Insights** ### **RNA-Based Therapeutics Market Technology Outlook** ### **RNA-Based Therapeutics Market Application Outlook** ### **RNA-Based Therapeutics Market End Use Outlook** ### **RNA-Based Therapeutics Market Delivery Method Outlook** ## Market Drivers ### Supportive Regulatory Framework The regulatory landscape in Germany is becoming increasingly supportive of the rna based-therapeutics market. Regulatory bodies are streamlining approval processes for innovative therapies, which is crucial for accelerating the development and commercialization of rna-based treatments. Recent initiatives have focused on providing clear guidelines for the evaluation of rna therapeutics, thereby reducing the time and cost associated with bringing new products to market. This supportive environment is likely to encourage investment in research and development, as companies feel more confident in navigating the regulatory landscape. Consequently, the rna based-therapeutics market is expected to benefit from a more efficient pathway to market entry, fostering innovation and competition. ### Advancements in Delivery Mechanisms Innovations in delivery mechanisms are playing a crucial role in the expansion of the rna based-therapeutics market. In Germany, researchers are developing novel methods to enhance the stability and efficacy of rna therapeutics, which is essential for their successful application in clinical settings. For instance, lipid nanoparticles and viral vectors are being explored to improve the delivery of rna molecules to target cells. These advancements not only increase the therapeutic potential of rna-based treatments but also address previous challenges related to bioavailability and off-target effects. As these technologies mature, they are likely to facilitate the entry of new rna therapeutics into the market, thereby broadening treatment options for patients. ### Growing Demand for Targeted Therapies The rna based-therapeutics market in Germany is experiencing a notable surge in demand for targeted therapies. This trend is largely driven by the increasing prevalence of genetic disorders and chronic diseases, which necessitate more precise treatment options. According to recent data, the market is projected to grow at a CAGR of approximately 15% over the next five years. This growth is indicative of a broader shift towards personalized medicine, where therapies are tailored to individual genetic profiles. As healthcare providers and patients alike seek more effective treatment modalities, the rna based-therapeutics market is positioned to meet these needs, thereby enhancing patient outcomes and potentially reducing healthcare costs in the long run. ### Rising Public Awareness and Acceptance Public awareness and acceptance of rna based-therapeutics are on the rise in Germany, which is positively impacting the market. As educational initiatives and media coverage increase, more individuals are becoming informed about the potential benefits of rna therapies. This growing awareness is crucial for fostering patient acceptance and encouraging healthcare providers to consider rna-based options in their treatment protocols. Additionally, as patients demand more innovative therapies, the rna based-therapeutics market is likely to see an increase in adoption rates. This shift in public perception may also influence policy decisions, leading to further support for research and funding in the field, thereby enhancing the overall landscape for rna therapeutics. ### Increased Collaboration Between Academia and Industry There is a growing trend of collaboration between academic institutions and industry players in the rna based-therapeutics market in Germany. These partnerships are essential for translating research findings into viable therapeutic solutions. By leveraging academic expertise in molecular biology and genetics, companies can enhance their rna therapeutic development processes. Furthermore, such collaborations often lead to shared resources and funding opportunities, which can significantly reduce the financial burden associated with research and development. As these partnerships continue to flourish, they are likely to accelerate the pace of innovation within the rna based-therapeutics market, ultimately benefiting patients through the introduction of new and effective therapies. ## Future Outlook The [RNA Based Therapeutics Market](https://www.marketresearchfuture.com/reports/rna-based-therapeutics-market-19244) is projected to grow at a 6.1% CAGR from 2025 to 2035, driven by advancements in gene editing and personalized medicine. **New opportunities:** - Development of targeted delivery systems for RNA therapies. - Expansion into emerging markets with tailored RNA solutions. - Partnerships with biotech firms for innovative RNA-based drug development. By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic collaborations. ## Segment Insights ### By Technology: mRNA Therapeutics (Largest) vs. CRISPR Technology (Fastest-Growing) In the Germany RNA-based therapeutics market, the distribution of market share among various technologies reveals that mRNA Therapeutics holds the largest share due to its robust applications and ongoing successful clinical trials. RNA Interference and Antisense Oligonucleotides also contribute significantly but trail behind. CRISPR Technology, while smaller in current share, is rapidly gaining traction as it revolutionizes gene editing and therapeutic applications, garnering substantial attention and investment. The growth trends in this segment are shaped by advancements in technology and an increasing focus on personalized medicine. mRNA Therapeutics is bolstered by its success in vaccine development, showcasing its capabilities beyond traditional therapies. In contrast, CRISPR Technology is recognized as the fastest-growing, driven by its potential to address genetic disorders and cancers. The demand for more effective and targeted treatments is expected to further fuel growth across these technologies in the coming years. Technology: mRNA Therapeutics (Dominant) vs. CRISPR Technology (Emerging) mRNA Therapeutics stands out as the dominant force in the Germany rna based-therapeutics market, owing to its significant role in recent vaccine developments, particularly during health crises. Its established market presence and the adaptability of mRNA technology for various therapeutic applications help maintain its lead. On the other hand, CRISPR Technology is emerging rapidly, known for its groundbreaking ability to edit genes precisely. This technology promises novel solutions to genetic disorders and has captured the interest of researchers and investors alike. Both segments, while distinct, are vital in shaping the future landscape of therapeutics, fulfilling the growing need for efficient and targeted treatments. ### By Application: Oncology (Largest) vs. Infectious Diseases (Fastest-Growing) In the Germany RNA-based therapeutics market, Oncology represents the largest segment, capturing a significant portion of the overall market share. This dominance is fueled by increasing prevalence in cancer cases and ongoing advancements in therapeutic technologies specifically targeted at oncology applications. Meanwhile, Infectious Diseases is emerging as the fastest-growing segment, as there is a rising focus on combating viral infections and other communicable diseases through innovative rna-based solutions. Growth trends show that the demand for therapies addressing Genetic Disorders and Cardiovascular Diseases is also on the rise, but they currently lag behind Oncology and Infectious Diseases. Key drivers in this space include increased investment in research and development, a growing understanding of rna mechanisms, and robust regulatory support that promotes faster approvals of rna-based therapies. Oncology: Dominant vs. Infectious Diseases: Emerging Oncology remains the dominant application segment, characterized by a vast array of rna-based therapies designed to target cancerous cells and support personalized medicine approaches. This segment benefits from substantial investment by pharmaceutical companies and a well-established framework for clinical trials, which enables rapid advancements. In contrast, Infectious Diseases is rapidly emerging, fueled by the urgent need for effective treatments following global health crises. This segment emphasizes the development of innovative rna therapies that can adapt to evolving pathogens and deliver quicker responses to outbreaks, highlighting its dynamic nature and importance in modern healthcare. ### By End Use: Pharmaceutical Companies (Largest) vs. Contract Research Organizations (Fastest-Growing) In the Germany RNA-based therapeutics market, the distribution of market share among the key segments reveals that pharmaceutical companies hold a significant share, largely due to their established infrastructures and extensive research capabilities. Research institutions also contribute meaningfully, driven by innovative research endeavors, while contract research organizations are gaining momentum with increasing collaborations and outsourcing of R&D by pharma companies. Growth trends indicate a robust expansion in the Germany rna based-therapeutics market, particularly among contract research organizations, which are rapidly emerging as a preferred choice for pharmaceutical companies seeking efficiency. This trend is fueled by technological advancements in RNA therapeutics, coupled with supportive regulations. As the demand for effective therapies rises, both pharmaceutical companies and research institutions are expected to maintain their pivotal roles, while contract research organizations capitalize on the growing trend of outsourcing R&D. Pharmaceutical Companies: Dominant vs. Contract Research Organizations: Emerging Pharmaceutical companies dominate the Germany rna based-therapeutics market, characterized by their extensive resources, established distribution networks, and significant investments in research and development. They leverage existing expertise to innovate and bring RNA-based therapies to market, ensuring a steady pipeline of new treatments. Conversely, contract research organizations are emerging, driven by the need for agile R&D processes that can adapt to rapid advancements in technology. Their flexible operational models allow them to support pharmaceutical companies in drug development, making them valuable partners in the evolving landscape of RNA therapeutics. This synergy fosters innovation and streamlines the path from research to market. ### By Delivery Method: Viral Vectors (Largest) vs. Nanoparticles (Fastest-Growing) In the Germany RNA-based therapeutics market, market share distribution indicates that Viral Vectors hold the largest portion among delivery methods, due to their efficacy in gene delivery and established track records in numerous applications. Following them, Nanoparticles are gaining momentum and are projected to increase their market share as advancements in nanotechnology facilitate enhanced delivery mechanisms, enabling more targeted therapies. Growth trends show that while Viral Vectors remain the dominant delivery method, driven by ongoing clinical successes and regulatory approvals, Nanoparticles have emerged as the fastest-growing segment. This rise is attributed to innovative applications in drug delivery, improved biocompatibility, and increased research initiatives focusing on exploiting nanoparticle properties for delivering RNA therapeutics effectively. Viral Vectors (Dominant) vs. Nanoparticles (Emerging) Viral Vectors are characterized by their ability to efficiently deliver RNA-based drugs into target cells, often resulting in robust therapeutic responses. As a dominant player in the Germany rna based-therapeutics market, they benefit from a wealth of clinical data and established manufacturing protocols that enhance their attractiveness to developers. On the other hand, Nanoparticles represent an emerging segment, recognized for their potential in overcoming biological barriers and enabling controlled release of therapeutics. The flexibility of nanoparticle design supports targeting specific tissues, which is pivotal for enhancing treatment efficacy, making them a focal point for future innovations and research in RNA delivery. ## Competitive Benchmarking The rna based-therapeutics market in Germany is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on addressing unmet medical needs. Key players such as BioNTech (DE), Moderna (US), and CureVac (DE) are at the forefront, leveraging their technological advancements to enhance therapeutic efficacy. BioNTech (DE) has positioned itself as a leader in mRNA technology, focusing on personalized cancer therapies and infectious diseases, while Moderna (US) continues to expand its portfolio beyond vaccines into rare diseases and autoimmune disorders. CureVac (DE) is also making strides in optimizing its mRNA platform for various applications, indicating a collective emphasis on innovation that shapes the competitive environment. In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce operational costs. The market appears moderately fragmented, with several players vying for market share, yet the influence of major companies is substantial. This competitive structure fosters an environment where collaboration and strategic alliances are essential for growth, as companies seek to optimize their operations and expand their market reach. In October 2025, BioNTech (DE) announced a collaboration with a leading German research institution to develop novel mRNA-based therapies targeting rare genetic disorders. This partnership is strategically significant as it not only enhances BioNTech's research capabilities but also positions the company to tap into a niche market with high unmet needs. Such collaborations are likely to bolster BioNTech's competitive edge in the therapeutic landscape. In September 2025, Moderna (US) revealed plans to invest €200 million in a new manufacturing facility in Germany, aimed at increasing its production capacity for mRNA therapeutics. This move underscores Moderna's commitment to expanding its operational footprint in Europe and enhancing its supply chain efficiency. The establishment of this facility is expected to create numerous jobs and strengthen local economies, while also ensuring timely access to innovative therapies for patients. In August 2025, CureVac (DE) secured a strategic partnership with a major pharmaceutical company to co-develop mRNA vaccines for infectious diseases. This collaboration is indicative of the growing trend towards strategic alliances in the rna based-therapeutics market, as companies recognize the value of combining resources and expertise to accelerate development timelines and improve market access. As of November 2025, current trends in the rna based-therapeutics market include a heightened focus on digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to leverage shared knowledge and resources. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the importance of agility and responsiveness to changing healthcare needs. ## Recent News & Developments The Germany RNA-Based Therapeutics Market has seen significant developments in recent months. In September 2023, BioNTech announced a collaboration with GSK to further develop mRNA-based therapeutics for cancer treatment, highlighting the increasing focus on personalized medicine. Moreover, Moderna reported an extension of its manufacturing capabilities in Germany to facilitate the production of its mRNA vaccines and therapeutics, contributing to local employment and technological advancement. In July 2023, Pfizer and BioNTech’s joint venture reported promising results in their ongoing clinical trials for new mRNA therapies targeting infectious diseases. The market has also experienced growth, attributed to advancements in Research and Development by companies such as CureVac, which recently began a Phase 1 trial for its RNA-based cancer vaccine. There have been no recent mergers or acquisitions reported among the major companies, including Arcturus Therapeutics, Sangamo Therapeutics, and Evotec. The German government continues to support the biotechnology sector through funding and policies aimed at fostering innovation, further strengthening the market landscape for RNA-based therapeutics. These dynamics underscore the vital role that Germany plays in the advancement of RNA technology within the global healthcare framework. ## Report Scope | MARKET SIZE 2024 | 732.65(USD Million) | | --- | --- | | MARKET SIZE 2025 | 777.34(USD Million) | | MARKET SIZE 2035 | 1405.55(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.1% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Moderna (US), BioNTech (DE), Alnylam Pharmaceuticals (US), Ionis Pharmaceuticals (US), CureVac (DE), Sangamo Therapeutics (US), Arcturus Therapeutics (US), Translate Bio (US) | | Segments Covered | Technology, Application, End Use, Delivery Method | | Key Market Opportunities | Advancements in RNA delivery systems enhance therapeutic efficacy and expand treatment options in the rna based-therapeutics market. | | Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the RNA-based therapeutics market. | | Countries Covered | Germany | ## Frequently Asked Questions **Q: What is the current valuation of the RNA based-therapeutics market in Germany as of 2024?** A: The market valuation was $732.65 Million in 2024. **Q: What is the projected market valuation for RNA based-therapeutics in Germany by 2035?** A: The projected valuation for 2035 is $1405.55 Million. **Q: What is the expected CAGR for the RNA based-therapeutics market in Germany during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 6.1%. **Q: Which companies are considered key players in the RNA based-therapeutics market in Germany?** A: Key players include Moderna, BioNTech, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, CureVac, Sangamo Therapeutics, Arcturus Therapeutics, and Translate Bio. **Q: What are the main technology segments within the RNA based-therapeutics market in Germany?** A: Main technology segments include RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, and CRISPR Technology. **Q: How did the mRNA therapeutics segment perform in terms of valuation in 2024?** A: The mRNA therapeutics segment was valued at $300 Million in 2024 and is expected to reach $600 Million by 2035. **Q: What applications are driving the RNA based-therapeutics market in Germany?** A: Key applications include Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases. **Q: What was the valuation of the cardiovascular diseases application segment in 2024?** A: The cardiovascular diseases application segment was valued at $402.86 Million in 2024. **Q: Which end-use segments are prominent in the RNA based-therapeutics market in Germany?** A: Prominent end-use segments include Pharmaceutical Companies, Research Institutions, and Contract Research Organizations. **Q: What delivery methods are utilized in the RNA based-therapeutics market in Germany?** A: Delivery methods include Liposomes, Nanoparticles, Viral Vectors, and Electroporation. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/germany-rna-based-therapeutics-market-52651*